RRx-001 is an anticancer agent that subjects cancer cells to reactive oxygen/ nitrogen species (ROS/RNS) and acts as an epigenetic modifier. We have used a thiol-bearing MRI contrast agent, Gd-LC7-SH, to investigate the pharmacodynamics of RRx-001 in CHP-100 Ewing’s Sarcoma,… Read More
Purpose: To determine whether deposition characteristics of ferumoxytol (FMX) iron nanoparticles in tumors, identiﬁed by quantitative MRI, may predict tumor lesion response to nanoli-posomal irinotecan (nal-IRI). Experimental Design: Eligible patients with previously trea-ted solid tumors had FMX-MRI scans before and… Read More
Ramanathan R.K., Korn R.L., Chiorean E.G., Liu H. & Von Hoff D.D. “Positron emission tomography (PET) as a predictive measure in patients with metastatic pancreatic cancer and normal CA19-9 levels at baseline.” Ann Oncol., 00: 1–2, (2016). To read more… Read More
11th Annual TOP Conference – Don’t Forget Clinical Trials Imaging Endpoints CMO and Founder, Ronald Korn, MD., Ph.D. presents “New Imaging Techniques to Aid Creative Clinical Trial Designs.” This talk will cover the role of imaging in oncology clinical trials… Read More
Dr. Ron Korn, founder and Chief Medical Officer of Imaging Endpoints Core Lab will be a featured speaker at the Cancer Treatment Centers of America® (CTCA) Western Regional Medical Center (Western) Annual New Treatments in Oncology (ANTO) conference. This conference focuses on advances in cancer research, new treatments and patient care.